Ipsen's Stock Hits a New Historical High at €167.80 After a 62% Rally Over the Year

New Record High for Ipsen at €167.80

This morning, Ipsen set a new absolute record at €167.80, erasing the previous peak from April 2nd. After reaching this high, the stock slightly declined by 0.36% to €166.90 mid-morning, in a supportive market environment: the CAC 40 is up by 1.33% during the session, while the SBF 120 advances in similar proportions. The recent trajectory of the biopharmaceutical group is remarkable. Over three months, the stock has risen by nearly 38%, and over a year, it has increased by more than 62%. The share price is now significantly above its 200-day moving average (€125.55) and its 50-day moving average (€151.50), indicating a firmly established upward trend. The next financial event is scheduled for April 16th with the publication of the first quarter 2026 revenue, an event that could confirm or adjust this momentum.

Technical Breakthrough at €167.40 Resistance

Breaking through the resistance identified at €167.40 is a notable technical event for the stock. By reaching €167.80 and then oscillating around €166.90, the price is above the upper boundary of the Bollinger Bands (€165.56), a positioning that signals a potential overbought situation. This type of configuration may precede a phase of consolidation or technical correction in the short term. The RSI, an indicator measuring the relative strength of the movement, is at 68, close to the threshold of 70 generally associated with an overbought zone. Although this level has not yet been exceeded, the conjunction of these two signals calls for caution in the very short term. In terms of comparable sector values, the session presents a mixed picture: Sanofi is up by 0.85%, while UCB is down by 1.36%. The most relevant support is at €148.40, more than 11% below the current price, illustrating the magnitude of the rally achieved in recent weeks.